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Introduction
o Evidence shows the efficacy of 
radiation therapy relies on 
interferon (IFN) signaling.
o Radiotherapy (RT), in a type 1 IFN-
dependent manner , promotes 
innate immune responses that 
support an adaptive immune 
response and anti-tumor immunity. 
o Direct administration of interferon 
to patients has adverse outcomes.
o Thus, it is important to find and 
target pathways (other than the 
already stablished cGAS-STING 
pathway) to improve RT efficacy.
o SR1001 (RORα agonist) and 
GSK4112 (Rev-erbα agonist) were 
identified in a drug screen for IFNb
augmentation.
o Both are involved in the immune 
system and the circadian rhythm.
o We hypothesized that RORα 
and Rev-erbα work together 
with radiation to augment type 
1 IFN production.
Conclusion
o The results show that RORα and Rev-erbα work 
together with radiation to augment type 1 IFN 
production.
o Since both RORα and Rev-erbα are circadian 
controlled, they may exist a link between the 
circadian rhythm and the immune response to 
radiation.
o Future directions will focus on determining if the 
time of drug and radiation delivery relative to the 
24-hour circadian cycle plays a role in increasing 
RT induced anti-tumor immunity.
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Fig. 2 Relative mRNA expression for 
IFNb1 and CCL5 (downstream of 
IFNb1) in radiated and untreated cells.
IFNB expression in cells treated with radiation + drug
Fig. 3 Relative mRNA expression for 
IFNb1 and CCL5 in cells treated with 
radiation and drugs.
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